Biocon Limited

Biocon Limited is a biopharmaceutical company engaged in the research, development, and manufacturing of pharmaceutical products. The company is known for its focus on innovating affordable therapies for chronic conditions in areas like oncology, diabetes, and autoimmune diseases. A key aspect of Biocon's operations involves biosimilars, where it leverages advanced science to create biologic products that are nearly identical to their original branded counterparts. This focus not only enhances therapeutic options for patients but also helps in reducing the cost burden on healthcare systems. Biocon Limited serves a global market, with significant emphasis on emerging markets as well as developed economies, making a notable impact in the pharmaceuticals and biotechnology industries. The company is a leader in supplying insulin and monoclonal antibodies, and its products reach over 120 countries. Biocon continuously invests in R&D to bolster its pipeline of products, thereby playing a critical role in the healthcare sector by improving access to essential medicines. Headquartered in Bangalore, India, Biocon maintains collaborations and partnerships with global pharmaceutical corporations, driving its objectives of expanding access to biosimilars and innovative biologics.